| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 23 | 2025 | 302 | 5.240 |
Why?
|
| Stress, Psychological | 5 | 2025 | 661 | 1.880 |
Why?
|
| Puberty | 2 | 2025 | 31 | 1.790 |
Why?
|
| Nicotinic Agonists | 6 | 2019 | 88 | 1.730 |
Why?
|
| Mice, Inbred C57BL | 21 | 2025 | 1869 | 1.540 |
Why?
|
| Fatty Liver | 5 | 2024 | 77 | 1.480 |
Why?
|
| Cushing Syndrome | 2 | 2020 | 5 | 1.240 |
Why?
|
| Hypothyroidism | 3 | 2025 | 26 | 1.170 |
Why?
|
| Triiodothyronine | 3 | 2025 | 36 | 1.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 760 | 1.050 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 830 | 0.990 |
Why?
|
| Male | 49 | 2025 | 23409 | 0.980 |
Why?
|
| Proprotein Convertase 2 | 7 | 2013 | 19 | 0.980 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2025 | 3 | 0.930 |
Why?
|
| Mice | 32 | 2025 | 6644 | 0.910 |
Why?
|
| Hormone Replacement Therapy | 1 | 2025 | 49 | 0.910 |
Why?
|
| Niacinamide | 1 | 2024 | 16 | 0.850 |
Why?
|
| Morphine | 4 | 2013 | 69 | 0.850 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 29 | 0.840 |
Why?
|
| Animals | 46 | 2025 | 16992 | 0.840 |
Why?
|
| Neurosecretory Systems | 1 | 2024 | 17 | 0.830 |
Why?
|
| Hepatocytes | 5 | 2012 | 80 | 0.800 |
Why?
|
| Endoribonucleases | 1 | 2023 | 25 | 0.780 |
Why?
|
| Smoking | 6 | 2022 | 1024 | 0.770 |
Why?
|
| Melatonin | 1 | 2023 | 82 | 0.760 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2008 | 35 | 0.750 |
Why?
|
| Corticosterone | 6 | 2019 | 90 | 0.740 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 161 | 0.720 |
Why?
|
| Analgesics, Opioid | 4 | 2013 | 252 | 0.720 |
Why?
|
| Sex Characteristics | 1 | 2024 | 258 | 0.720 |
Why?
|
| Insulin Resistance | 6 | 2019 | 201 | 0.710 |
Why?
|
| Carbohydrate Dehydrogenases | 5 | 2019 | 12 | 0.710 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 161 | 0.700 |
Why?
|
| Prediabetic State | 3 | 2012 | 69 | 0.690 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 40 | 0.670 |
Why?
|
| Adrenal Glands | 1 | 2020 | 18 | 0.660 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 7 | 2019 | 16 | 0.660 |
Why?
|
| Proprotein Convertase 1 | 6 | 2013 | 10 | 0.640 |
Why?
|
| Alcohol Drinking | 1 | 2025 | 609 | 0.630 |
Why?
|
| Hyperglycemia | 2 | 2015 | 61 | 0.620 |
Why?
|
| Humans | 34 | 2025 | 43102 | 0.620 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 184 | 0.610 |
Why?
|
| Insulin | 4 | 2016 | 258 | 0.610 |
Why?
|
| Aerosols | 1 | 2019 | 54 | 0.600 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 96 | 0.600 |
Why?
|
| Mexican Americans | 1 | 2021 | 226 | 0.590 |
Why?
|
| Life Style | 1 | 2021 | 334 | 0.590 |
Why?
|
| Stroke Volume | 1 | 2019 | 122 | 0.570 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 114 | 0.570 |
Why?
|
| Blood Glucose | 6 | 2019 | 389 | 0.550 |
Why?
|
| Dexamethasone | 1 | 2018 | 55 | 0.550 |
Why?
|
| Adolescent | 7 | 2025 | 6081 | 0.540 |
Why?
|
| Smoking Cessation | 3 | 2023 | 590 | 0.530 |
Why?
|
| Testosterone | 4 | 2025 | 211 | 0.530 |
Why?
|
| Oxidative Stress | 10 | 2024 | 1003 | 0.530 |
Why?
|
| Female | 23 | 2025 | 24698 | 0.530 |
Why?
|
| Diet | 2 | 2021 | 826 | 0.530 |
Why?
|
| Behavior, Animal | 2 | 2019 | 373 | 0.520 |
Why?
|
| Atherosclerosis | 1 | 2019 | 169 | 0.520 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2013 | 52 | 0.500 |
Why?
|
| Pituitary Neoplasms | 2 | 2008 | 5 | 0.490 |
Why?
|
| Hypopituitarism | 2 | 2008 | 2 | 0.490 |
Why?
|
| Vitamin D | 2 | 2012 | 196 | 0.490 |
Why?
|
| Human Growth Hormone | 2 | 2008 | 21 | 0.480 |
Why?
|
| Brain | 3 | 2013 | 1472 | 0.460 |
Why?
|
| Lipolysis | 4 | 2023 | 20 | 0.450 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 49 | 0.450 |
Why?
|
| Drug Resistance | 1 | 2015 | 96 | 0.440 |
Why?
|
| Drug Monitoring | 1 | 2015 | 69 | 0.440 |
Why?
|
| Health Status Disparities | 1 | 2021 | 719 | 0.440 |
Why?
|
| Adolescent Development | 2 | 2025 | 40 | 0.430 |
Why?
|
| Mice, Obese | 6 | 2020 | 42 | 0.420 |
Why?
|
| Protein Precursors | 4 | 2006 | 59 | 0.420 |
Why?
|
| Pituitary Gland | 4 | 2020 | 60 | 0.420 |
Why?
|
| Endocrine System Diseases | 2 | 2012 | 16 | 0.410 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2013 | 15 | 0.410 |
Why?
|
| Morphine Dependence | 1 | 2013 | 23 | 0.400 |
Why?
|
| Narcotics | 1 | 2013 | 29 | 0.400 |
Why?
|
| Body Weight | 6 | 2016 | 429 | 0.400 |
Why?
|
| Liver | 5 | 2024 | 511 | 0.400 |
Why?
|
| Obesity | 4 | 2023 | 1151 | 0.390 |
Why?
|
| Adipose Tissue | 4 | 2019 | 182 | 0.380 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 183 | 0.380 |
Why?
|
| Thyrotropin-Releasing Hormone | 3 | 2006 | 13 | 0.370 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 2 | 0.370 |
Why?
|
| Eating | 1 | 2013 | 167 | 0.370 |
Why?
|
| Child | 4 | 2025 | 3443 | 0.360 |
Why?
|
| Body Composition | 2 | 2014 | 159 | 0.360 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2012 | 26 | 0.360 |
Why?
|
| Glucocorticoids | 3 | 2019 | 91 | 0.360 |
Why?
|
| Cholecalciferol | 1 | 2011 | 20 | 0.350 |
Why?
|
| Sex Factors | 2 | 2025 | 1028 | 0.350 |
Why?
|
| Fasting | 1 | 2011 | 56 | 0.350 |
Why?
|
| Cotinine | 3 | 2020 | 44 | 0.340 |
Why?
|
| Middle Aged | 11 | 2025 | 12222 | 0.340 |
Why?
|
| Gene Expression Regulation | 5 | 2013 | 1070 | 0.340 |
Why?
|
| Hydrocortisone | 3 | 2020 | 93 | 0.340 |
Why?
|
| Mice, Knockout | 10 | 2019 | 1035 | 0.330 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2020 | 388 | 0.330 |
Why?
|
| Adult | 12 | 2025 | 13872 | 0.330 |
Why?
|
| Kidney | 2 | 2025 | 372 | 0.330 |
Why?
|
| Androgens | 3 | 2014 | 106 | 0.330 |
Why?
|
| Endocrine System | 1 | 2009 | 12 | 0.310 |
Why?
|
| Opiate Alkaloids | 1 | 2009 | 8 | 0.310 |
Why?
|
| Blood Pressure | 2 | 2025 | 666 | 0.310 |
Why?
|
| Feeding Behavior | 1 | 2013 | 469 | 0.310 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 1596 | 0.310 |
Why?
|
| Thyroxine | 3 | 2025 | 22 | 0.300 |
Why?
|
| Risk Factors | 4 | 2025 | 3994 | 0.280 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2008 | 2 | 0.280 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2025 | 15 | 0.270 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 1 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.270 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 81 | 0.260 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2014 | 166 | 0.260 |
Why?
|
| Animal Feed | 2 | 2020 | 53 | 0.260 |
Why?
|
| Adenoma | 1 | 2008 | 96 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1124 | 0.250 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2006 | 6 | 0.250 |
Why?
|
| Proprotein Convertases | 1 | 2006 | 8 | 0.250 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 41 | 0.250 |
Why?
|
| Carcinoma | 1 | 2007 | 108 | 0.250 |
Why?
|
| RNA, Messenger | 6 | 2013 | 1271 | 0.250 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 55 | 0.250 |
Why?
|
| Immune System | 2 | 2023 | 41 | 0.250 |
Why?
|
| Adiposity | 3 | 2019 | 157 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 66 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2006 | 91 | 0.230 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 2 | 2025 | 6 | 0.230 |
Why?
|
| Pyrazines | 2 | 2023 | 32 | 0.230 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 153 | 0.230 |
Why?
|
| Hypogonadism | 3 | 2012 | 23 | 0.230 |
Why?
|
| Apoptosis | 3 | 2020 | 1568 | 0.220 |
Why?
|
| Narcotic Antagonists | 3 | 2013 | 78 | 0.220 |
Why?
|
| Young Adult | 3 | 2021 | 5080 | 0.220 |
Why?
|
| Weight Gain | 2 | 2016 | 139 | 0.220 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2013 | 131 | 0.220 |
Why?
|
| Retrospective Studies | 3 | 2020 | 2544 | 0.210 |
Why?
|
| Prolactinoma | 1 | 2004 | 1 | 0.210 |
Why?
|
| Ergolines | 1 | 2004 | 2 | 0.210 |
Why?
|
| Hyperprolactinemia | 1 | 2004 | 3 | 0.210 |
Why?
|
| Phenotype | 2 | 2023 | 780 | 0.210 |
Why?
|
| Conditioning, Operant | 3 | 2013 | 90 | 0.210 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 1 | 0.210 |
Why?
|
| Pituitary Diseases | 1 | 2004 | 2 | 0.210 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2004 | 12 | 0.210 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 182 | 0.210 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 10 | 0.210 |
Why?
|
| Tobacco Use Disorder | 2 | 2023 | 250 | 0.210 |
Why?
|
| Reward | 3 | 2013 | 112 | 0.210 |
Why?
|
| Carotid Arteries | 1 | 2004 | 36 | 0.210 |
Why?
|
| Abdominal Fat | 2 | 2014 | 21 | 0.200 |
Why?
|
| Postmenopause | 2 | 2014 | 141 | 0.200 |
Why?
|
| Feedback | 1 | 2023 | 56 | 0.200 |
Why?
|
| Endocrine Glands | 1 | 2003 | 3 | 0.200 |
Why?
|
| Palmitates | 1 | 2023 | 15 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2020 | 68 | 0.200 |
Why?
|
| Leptin | 2 | 2004 | 118 | 0.200 |
Why?
|
| Hep G2 Cells | 1 | 2023 | 63 | 0.200 |
Why?
|
| Rats | 8 | 2013 | 3735 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 241 | 0.190 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 561 | 0.190 |
Why?
|
| Chagas Disease | 1 | 2004 | 104 | 0.190 |
Why?
|
| Adolescent Behavior | 1 | 2025 | 281 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 526 | 0.180 |
Why?
|
| Fatty Acids | 1 | 2023 | 134 | 0.180 |
Why?
|
| United States | 2 | 2025 | 5205 | 0.180 |
Why?
|
| Age Factors | 1 | 2025 | 1154 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1063 | 0.180 |
Why?
|
| Hospital Administrators | 1 | 2021 | 2 | 0.180 |
Why?
|
| beta-Endorphin | 3 | 2012 | 17 | 0.180 |
Why?
|
| Prevalence | 2 | 2021 | 1612 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2013 | 1766 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2021 | 31 | 0.170 |
Why?
|
| Vitamin D Deficiency | 1 | 2002 | 107 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2020 | 23 | 0.170 |
Why?
|
| Glucose Tolerance Test | 2 | 2012 | 75 | 0.160 |
Why?
|
| Buffers | 1 | 2020 | 17 | 0.160 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2006 | 185 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 242 | 0.160 |
Why?
|
| Regression Analysis | 1 | 2021 | 490 | 0.160 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 263 | 0.160 |
Why?
|
| Aged | 5 | 2025 | 8214 | 0.160 |
Why?
|
| Cytokines | 1 | 2023 | 678 | 0.150 |
Why?
|
| Dietary Fats | 2 | 2011 | 117 | 0.150 |
Why?
|
| Cells, Cultured | 4 | 2008 | 1621 | 0.150 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 44 | 0.150 |
Why?
|
| Arginine Vasopressin | 2 | 2012 | 13 | 0.150 |
Why?
|
| Sexuality | 2 | 2014 | 56 | 0.150 |
Why?
|
| Heart | 1 | 2020 | 184 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 1019 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 187 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 192 | 0.140 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 138 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 67 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2021 | 986 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.140 |
Why?
|
| Hypertension | 1 | 2025 | 835 | 0.140 |
Why?
|
| Myocardium | 1 | 2020 | 263 | 0.140 |
Why?
|
| Obesity, Abdominal | 1 | 2018 | 29 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2019 | 575 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 191 | 0.140 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 934 | 0.130 |
Why?
|
| Calcium | 3 | 2007 | 491 | 0.130 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2020 | 41 | 0.130 |
Why?
|
| Benzamides | 1 | 2018 | 81 | 0.130 |
Why?
|
| Naltrexone | 2 | 2013 | 34 | 0.120 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2006 | 25 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 532 | 0.120 |
Why?
|
| Depression | 1 | 2023 | 863 | 0.120 |
Why?
|
| Triglycerides | 2 | 2014 | 147 | 0.120 |
Why?
|
| Medical Records | 1 | 2015 | 48 | 0.110 |
Why?
|
| Parathyroid Hormone | 2 | 2007 | 41 | 0.110 |
Why?
|
| Urban Health Services | 1 | 2015 | 44 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 68 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 234 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2014 | 38 | 0.110 |
Why?
|
| Mutation | 1 | 2019 | 1177 | 0.110 |
Why?
|
| Los Angeles | 1 | 2015 | 394 | 0.100 |
Why?
|
| Anorexia | 1 | 2013 | 5 | 0.100 |
Why?
|
| KATP Channels | 1 | 2013 | 10 | 0.100 |
Why?
|
| Drug Implants | 1 | 2013 | 20 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 518 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 36 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2014 | 70 | 0.100 |
Why?
|
| Pain Threshold | 1 | 2013 | 34 | 0.100 |
Why?
|
| Glucose | 2 | 2005 | 244 | 0.100 |
Why?
|
| Gene Expression | 2 | 2008 | 701 | 0.100 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2013 | 64 | 0.100 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2013 | 14 | 0.100 |
Why?
|
| Antiporters | 1 | 2013 | 14 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2013 | 91 | 0.100 |
Why?
|
| Energy Intake | 2 | 2011 | 164 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 27 | 0.100 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2010 | 15 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 436 | 0.090 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 126 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 108 | 0.090 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 52 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2012 | 317 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2012 | 307 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 2012 | 31 | 0.090 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 48 | 0.090 |
Why?
|
| Pyrroles | 1 | 2012 | 72 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 150 | 0.090 |
Why?
|
| Time Factors | 2 | 2013 | 1857 | 0.090 |
Why?
|
| Analgesia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 213 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 139 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2010 | 26 | 0.080 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2010 | 3 | 0.080 |
Why?
|
| Enkephalins | 2 | 2010 | 31 | 0.080 |
Why?
|
| Animals, Newborn | 3 | 2020 | 352 | 0.080 |
Why?
|
| Indoles | 1 | 2012 | 187 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 28 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 32 | 0.080 |
Why?
|
| Mitochondria | 1 | 2014 | 523 | 0.080 |
Why?
|
| Aging | 2 | 2013 | 783 | 0.080 |
Why?
|
| Cocaine | 1 | 2012 | 251 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1723 | 0.070 |
Why?
|
| Models, Biological | 2 | 2016 | 712 | 0.070 |
Why?
|
| Carbenoxolone | 1 | 2008 | 10 | 0.070 |
Why?
|
| Deoxyglucose | 1 | 2008 | 18 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 181 | 0.070 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thyroidectomy | 1 | 2007 | 10 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cell Line | 3 | 2013 | 1410 | 0.070 |
Why?
|
| Hypothalamus | 2 | 2005 | 120 | 0.070 |
Why?
|
| Creatinine | 1 | 2007 | 102 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2020 | 160 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 59 | 0.060 |
Why?
|
| Homeostasis | 1 | 2008 | 192 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 27 | 0.060 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2006 | 2 | 0.060 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2006 | 2 | 0.060 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2006 | 6 | 0.060 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 17 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2009 | 195 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2006 | 26 | 0.060 |
Why?
|
| Spatial Behavior | 1 | 2006 | 22 | 0.060 |
Why?
|
| Adipocytes | 2 | 2018 | 60 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2006 | 35 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 240 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2006 | 42 | 0.060 |
Why?
|
| Glucagon | 1 | 2005 | 7 | 0.060 |
Why?
|
| Neurophysins | 1 | 2005 | 1 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 16 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2006 | 93 | 0.060 |
Why?
|
| Retinoid X Receptor beta | 1 | 2005 | 1 | 0.060 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2005 | 3 | 0.060 |
Why?
|
| Oxytocin | 1 | 2005 | 24 | 0.060 |
Why?
|
| Locomotion | 1 | 2006 | 105 | 0.060 |
Why?
|
| Mifepristone | 1 | 2005 | 34 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 54 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 71 | 0.060 |
Why?
|
| Response Elements | 1 | 2005 | 55 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2005 | 91 | 0.050 |
Why?
|
| Cheek | 1 | 2004 | 13 | 0.050 |
Why?
|
| Tretinoin | 1 | 2005 | 50 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1285 | 0.050 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 6 | 0.050 |
Why?
|
| Prolactin | 1 | 2004 | 65 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 71 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 280 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2004 | 30 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 665 | 0.050 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pregnancy | 3 | 2020 | 1772 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 549 | 0.050 |
Why?
|
| Self Administration | 2 | 2013 | 69 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 150 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2007 | 1604 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 306 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 247 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2013 | 283 | 0.050 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2002 | 14 | 0.050 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2002 | 2 | 0.050 |
Why?
|
| Phosphates | 1 | 2002 | 54 | 0.050 |
Why?
|
| Trypanosoma cruzi | 1 | 2004 | 157 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 277 | 0.050 |
Why?
|
| Neurons | 2 | 2006 | 1263 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 592 | 0.040 |
Why?
|
| Bone Density | 1 | 2002 | 103 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 316 | 0.040 |
Why?
|
| Hippocampus | 1 | 2005 | 594 | 0.040 |
Why?
|
| Mecamylamine | 1 | 2020 | 21 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2020 | 29 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 129 | 0.040 |
Why?
|
| Spironolactone | 1 | 2021 | 36 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 105 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 587 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 375 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 142 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 139 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 167 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 99 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 452 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2020 | 123 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 59 | 0.040 |
Why?
|
| Public Health | 1 | 2023 | 424 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 299 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 147 | 0.040 |
Why?
|
| Cognition | 1 | 2002 | 473 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 536 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 380 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 616 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2016 | 36 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2019 | 883 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 34 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 148 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 758 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1455 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 12 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 37 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 127 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2013 | 15 | 0.030 |
Why?
|
| Arousal | 1 | 2014 | 95 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 94 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 53 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 28 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 95 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2676 | 0.020 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 59 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 135 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 15 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2013 | 41 | 0.020 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 100 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 2013 | 104 | 0.020 |
Why?
|
| Dopamine | 1 | 2013 | 275 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 456 | 0.020 |
Why?
|
| Dynorphins | 1 | 2010 | 17 | 0.020 |
Why?
|
| Naloxone | 1 | 2010 | 56 | 0.020 |
Why?
|
| Nociceptors | 1 | 2010 | 30 | 0.020 |
Why?
|
| Swimming | 1 | 2010 | 41 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 51 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2010 | 141 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 151 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2010 | 183 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 157 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2014 | 638 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2157 | 0.020 |
Why?
|
| Median Eminence | 1 | 2006 | 10 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 2006 | 8 | 0.020 |
Why?
|
| Proglucagon | 1 | 2005 | 2 | 0.010 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 2 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2004 | 28 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 52 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2004 | 61 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 311 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 60 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 30 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 43 | 0.010 |
Why?
|
| Proteome | 1 | 2005 | 152 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 652 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 695 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 233 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1180 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 268 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1542 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2004 | 925 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 497 | 0.010 |
Why?
|